• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮肤鳞状细胞癌(cSCC)危险因素评估的当前方法及注意事项:一项叙述性综述

Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review.

作者信息

Farberg Aaron S, Fitzgerald Alison L, Ibrahim Sherrif F, Tolkachjov Stan N, Soleymani Teo, Douglas Leah M, Kurley Sarah J, Arron Sarah T

机构信息

Baylor Scott & White Health System, Baylor University Medical Center, Dallas, TX, USA.

Castle Biosciences, Inc., Friendswood, TX, USA.

出版信息

Dermatol Ther (Heidelb). 2022 Feb;12(2):267-284. doi: 10.1007/s13555-021-00673-y. Epub 2022 Jan 7.

DOI:10.1007/s13555-021-00673-y
PMID:34994967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8850485/
Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, and the number of deaths due to cSCC is estimated to be greater than the number attributed to melanoma. While the majority of cSCC tumors are resectable with clear margins by standard excision practices, some lesions exhibit high-risk factors for which there is evidence of their association with recurrence, metastasis, and disease-specific death. The most commonly used staging systems and guidelines in the USA for cSCC are based on these clinical and pathologic high-risk factors; however, these are limited in their ability to predict adverse events, thus posing a challenge for implementing risk-directed patient management. Since the development of local recurrence and/or metastasis has a profound impact on the survival of patients with cSCC, accurate identification of patients at high risk for poor outcomes is critical, potentially allowing for early and appropriate adjuvant therapy. This review summarizes the current cSCC literature with a focus on how differing clinical assessments within each of the five selected risk factors (perineural invasion, differentiation, depth of invasion, size, and location) can influence the evaluation of patient outcomes, along with summarizing the utility of staging and guidelines, and highlighting the potential for molecular tools to improve upon cSCC risk assessment.

摘要

皮肤鳞状细胞癌(cSCC)是第二常见的皮肤癌形式,据估计,cSCC导致的死亡人数超过黑色素瘤导致的死亡人数。虽然大多数cSCC肿瘤可通过标准切除手术实现切缘清晰切除,但一些病变具有高危因素,有证据表明这些因素与复发、转移和疾病特异性死亡相关。美国最常用的cSCC分期系统和指南基于这些临床和病理高危因素;然而,它们预测不良事件的能力有限,因此对实施风险导向的患者管理构成挑战。由于局部复发和/或转移的发生对cSCC患者的生存有深远影响,准确识别预后不良的高危患者至关重要,这可能有助于早期进行适当的辅助治疗。本综述总结了当前cSCC的文献,重点关注五个选定风险因素(神经周围浸润、分化程度、浸润深度、大小和位置)中每个因素的不同临床评估如何影响患者预后的评估,同时总结分期和指南的效用,并强调分子工具在改善cSCC风险评估方面的潜力。

相似文献

1
Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review.皮肤鳞状细胞癌(cSCC)危险因素评估的当前方法及注意事项:一项叙述性综述
Dermatol Ther (Heidelb). 2022 Feb;12(2):267-284. doi: 10.1007/s13555-021-00673-y. Epub 2022 Jan 7.
2
Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.皮肤鳞状细胞癌:高危和转移性疾病综述。
Am J Clin Dermatol. 2016 Oct;17(5):491-508. doi: 10.1007/s40257-016-0207-3.
3
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.皮肤浸润性鳞状细胞癌的诊断与治疗:基于欧洲共识的跨学科指南
Eur J Cancer. 2015 Sep;51(14):1989-2007. doi: 10.1016/j.ejca.2015.06.110. Epub 2015 Jul 25.
4
Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study.预测皮肤鳞状细胞癌复发和死亡的因素:一项 10 年单机构队列研究。
JAMA Dermatol. 2013 May;149(5):541-7. doi: 10.1001/jamadermatol.2013.2139.
5
Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines.非黑色素瘤皮肤癌:英国国家多学科指南
J Laryngol Otol. 2016 May;130(S2):S125-S132. doi: 10.1017/S0022215116000554.
6
Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis.皮肤鳞状细胞癌复发、转移及疾病特异性死亡的危险因素:一项系统评价和Meta分析
JAMA Dermatol. 2016 Apr;152(4):419-28. doi: 10.1001/jamadermatol.2015.4994.
7
Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.40基因表达谱(40-GEP)检测结合皮肤鳞状细胞癌(cSCC)当前临床病理危险因素用于改善患者管理决策和疾病相关结局的临床效用:病例系列
Dermatol Ther (Heidelb). 2022 Feb;12(2):591-597. doi: 10.1007/s13555-021-00665-y. Epub 2021 Dec 23.
8
Cutaneous Squamous Cell Carcinoma of the Head and Neck: Pathological Features and What They Mean for Prognosis and Treatment.头颈部皮肤鳞状细胞癌:病理特征及其对预后和治疗的意义
Cancers (Basel). 2024 Aug 17;16(16):2866. doi: 10.3390/cancers16162866.
9
Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.皮肤鳞状细胞癌:晚期和高期肿瘤的治疗。
J Am Acad Dermatol. 2018 Feb;78(2):249-261. doi: 10.1016/j.jaad.2017.08.058.
10
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.欧洲多学科指南:侵袭性鳞状细胞皮肤癌 第 2 部分:治疗。
Eur J Cancer. 2020 Mar;128:83-102. doi: 10.1016/j.ejca.2020.01.008. Epub 2020 Feb 26.

引用本文的文献

1
Enhanced metastasis risk prediction in cutaneous squamous cell carcinoma using deep learning and computational histopathology.利用深度学习和计算组织病理学增强皮肤鳞状细胞癌转移风险预测
NPJ Precis Oncol. 2025 Sep 2;9(1):308. doi: 10.1038/s41698-025-01065-7.
2
Retrieval Augmented Generation-Enabled Large Language Model for Risk Stratification of Cutaneous Squamous Cell Carcinoma.用于皮肤鳞状细胞癌风险分层的基于检索增强生成的大语言模型
JAMA Dermatol. 2025 Jun 11. doi: 10.1001/jamadermatol.2025.1614.
3
PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights.用于皮肤鳞状细胞癌的程序性死亡受体配体1(PD-L1)抑制剂科斯贝利单抗:疗效、机制及临床试验见解的综合评估
Biomedicines. 2025 Apr 7;13(4):889. doi: 10.3390/biomedicines13040889.
4
Cutaneous squamous cell carcinoma-derived exosomal MicroRNA-31 acts as an oncogene by targeting the tumor suppressor RhoBTB1.皮肤鳞状细胞癌来源的外泌体微小RNA-31通过靶向肿瘤抑制因子RhoBTB1发挥致癌基因的作用。
Arch Dermatol Res. 2024 Dec 14;317(1):114. doi: 10.1007/s00403-024-03558-0.
5
Aberrant expression of B7-H4 and B7-H5 contributes to the development of cutaneous squamous cell carcinoma.B7-H4 和 B7-H5 的异常表达有助于皮肤鳞状细胞癌的发展。
Arch Dermatol Res. 2024 Jun 8;316(7):382. doi: 10.1007/s00403-024-03095-w.
6
Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.皮肤鳞状细胞癌的分子靶向治疗:最新进展与临床意义
EXCLI J. 2024 Feb 27;23:300-334. doi: 10.17179/excli2023-6489. eCollection 2024.
7
Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.整合40基因表达谱(40-GEP)检测可改善高风险皮肤鳞状细胞癌(cSCC)患者临床相关亚组中的转移风险分层。
Dermatol Ther (Heidelb). 2024 Mar;14(3):593-612. doi: 10.1007/s13555-024-01111-5. Epub 2024 Mar 1.
8
Use of the 40-gene Expression Profile (40-GEP) Test in Medicare-eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs.在符合医疗保险资格且被诊断为皮肤鳞状细胞癌(cSCC)的患者中使用40基因表达谱(40-GEP)检测来指导辅助放疗(ART)决策可显著降低医疗成本。
J Clin Aesthet Dermatol. 2024 Jan;17(1):41-44.
9
Mast Cell: A Mysterious Character in Skin Cancer.肥大细胞:皮肤癌中的神秘角色。
In Vivo. 2024 Jan-Feb;38(1):58-68. doi: 10.21873/invivo.13410.
10
The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.40基因表达谱(40-GEP)检测在皮肤鳞状细胞癌中的预后价值和临床应用:系统评价与Meta分析
Cancers (Basel). 2023 Apr 25;15(9):2456. doi: 10.3390/cancers15092456.

本文引用的文献

1
Cutaneous squamous cell carcinoma staging may influence management in users: A survey study.皮肤鳞状细胞癌分期可能会影响使用者的治疗管理:一项调查研究。
Cancer Med. 2022 Jan;11(1):94-103. doi: 10.1002/cam4.4426. Epub 2021 Nov 18.
2
Concordance of Squamous Cell Carcinoma Histologic Grading Among Dermatopathologists and Mohs Surgeons.皮肤科病理学家和 Mohs 外科医生之间的鳞状细胞癌组织学分级一致性。
Dermatol Surg. 2021 Nov 1;47(11):1433-1437. doi: 10.1097/DSS.0000000000003213.
3
Clinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management.整合基因表达谱分析于皮肤鳞状细胞癌管理的临床考量。
J Drugs Dermatol. 2021 Jun 1;20(6):5s-s11. doi: 10.36849/JDD.2021.6068.
4
Performance of Salamanca refinement of the T3-AJCC8 versus the Brigham and Women's Hospital and Tübingen alternative staging systems for high-risk cutaneous squamous cell carcinoma.萨兰那加改良 T3-AJCC8 分期系统与布里格姆妇女医院和图宾根替代分期系统在高危皮肤鳞状细胞癌中的表现比较。
J Am Acad Dermatol. 2021 Apr;84(4):938-945. doi: 10.1016/j.jaad.2020.12.020. Epub 2021 Jan 9.
5
Patterns of incidental perineural invasion and prognosis in cutaneous squamous cell carcinoma: A multicenter, retrospective cohort study.皮肤鳞状细胞癌中偶然神经侵犯模式与预后:一项多中心回顾性队列研究
J Am Acad Dermatol. 2021 Jun;84(6):1708-1712. doi: 10.1016/j.jaad.2020.08.017. Epub 2020 Aug 8.
6
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.验证一个 40 基因表达谱测试,以预测局限性高危皮肤鳞状细胞癌的转移风险。
J Am Acad Dermatol. 2021 Feb;84(2):361-369. doi: 10.1016/j.jaad.2020.04.088. Epub 2020 Apr 25.
7
Expression-based, consistent biomarkers for prognosis and diagnosis in lung cancer.基于表达的、一致的肺癌预后和诊断生物标志物。
Clin Transl Oncol. 2020 Oct;22(10):1867-1874. doi: 10.1007/s12094-020-02328-4. Epub 2020 Mar 16.
8
High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: Risk Factors for Recurrence and Impact of Adjuvant Treatment.头颈部高危皮肤鳞状细胞癌:复发的危险因素和辅助治疗的影响。
Laryngoscope. 2021 Jan;131(1):E136-E143. doi: 10.1002/lary.28564. Epub 2020 Feb 17.
9
Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre.面部中三分之一基底细胞癌和皮肤鳞状细胞癌局部复发的危险因素:基于单中心的15年回顾性分析
Eur J Dermatol. 2019 Oct 1;29(5):490-499. doi: 10.1684/ejd.2019.3643.
10
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.SWOG9313c 试验中三阴性乳腺癌患者 DNA 损伤免疫反应特征的验证。
J Clin Oncol. 2019 Dec 20;37(36):3484-3492. doi: 10.1200/JCO.19.00693. Epub 2019 Oct 28.